期刊文献+

特发性肺纤维化体液免疫学变化的临床意义 被引量:5

Clinical significance of changes of humoral immunity in patient with idiopathic pulmonary fibrosis
暂未订购
导出
摘要 目的探讨特发性肺纤维化体液免疫学变化的临床意义。方法回顾性分析该院收治的66例特发性肺纤维化(IPF)患者,观察记录IPF患者(研究组)的临床资料,研究组进行组内比较,同时研究组与66例健康成人(对照组)的血清学资料进行对比。结果研究组和对照组血清抗体ANA、RF、CCP、ds DNA、RNP、Scl-70、Sm/RNP、SSA、SSB、PR3差异无统计学意义(P>0.05)。自身抗体阳性的IPF患者和自身抗体阴性的IPF患者在女性、有吸烟史、雷诺氏症、需要长期氧疗、6 min步行试验后低氧血症、高分辨率CT(HRCT)可见明确的普通型间质性肺炎(UIP)表现,这些方面差异均无统计学意义(P>0.05)。结论自身抗体ANA、RF、CCP、ds DNA、RNP、Scl-70、Sm/RNP、SSA、SSB、PR3的变化与特发性肺纤维化无显著相关。 【Objective】To explore the clinical significance of humoral immune changes in patients with idiopathic pulmonary fibrosis(IPF). 【Methods】 A retrospective analysis was carried out in 66 patients with IPF(research group), the clinical data of the research group were reviewed and analyzed. The humoral immune changes of the research group and 66 cases of healthy adults(control group) were compared.【Results】There were no statistical differences in serum antibodies like ANA, RF, CCP, ds DNA, RNP, Scl-70, Sm/RNP, SSA, SSB and PR3 between the research group and the control group(P 〉 0.05). There were no significant differences between autoantibody positive patients with IPF and autoantibody negative IPF patients in the female sex, smoking history, Raynaud’s disease,long-term oxygen therapy, hypoxemia after 6 minutes walk test or clear manifestations of usual interstitial pneumonia(UIP) by high resolution CT(HRCT, P 〉 0.05). 【Conclusion】The changes of autoantibodies like ANA, RF, CCP,ds DNA, RNP, Scl-70, Sm/RNP, SSA, SSB and PR3 have no correlation with idiopathic pulmonary fibrosis.
出处 《中国现代医学杂志》 CAS 北大核心 2015年第18期41-45,共5页 China Journal of Modern Medicine
基金 国家自然科学基金项目(No:81371439)
关键词 特发性肺纤维化 自身抗体 抗核抗体 风湿因子 idiopathic pulmonary fibrosis autoantibody anti-nuclear antibody rheumatoid factor
  • 相关文献

参考文献21

  • 1NOBLE PW, ALBERA C, BRADFORD WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two ran- domised trials[J]. The Lancet, 2011, 377(9779): 1760-1769.
  • 2KING JR TE, PARDO A, SELMAN M. Idiopathic pulmonary fi- brosis[J]. The Lancet, 2011, 378(9807): 1949-1961.
  • 3HOO ZH, WHYTE MKB. Idiopathic pulmonary fibrosis[J]. Thorax, 2012, 67(8): 742-746.
  • 4RAGHU G, COLLARD HR, EGAN JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evi- dence-based guidelines for diagnosis and management[J]. Ameri- can Journal of Respiratory and Critical Care Medicine, 2011, 183(6): 788-824.
  • 5RICHELDI L, COSTABEL U, SELMAN M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis[J]. New England Journal of Medicine, 2011, 365(12): 1079-1087.
  • 6DU BOIS RM, WEYCKER D, ALBERA C, et al. Six-minute- walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference [J]. American Journal of Respiratory and Critical Care Medicine, 2011, 183(9): 1231-1237.
  • 7RYERSON CJ, HARTMAN T, ELICKER BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and em- physema in idiopathic pulmonary fibrosis combined pulmonary fibrosis and emphysema[J]. Chest Journal, 2013, 144(1): 234-240.
  • 8TANIGUCHI H, EBINA M, KONDOH Y, et al. Pirfenidone in idiopathic pulmonary fibrosis [J]. European Respiratory Journal, 2010, 35(4): 821-829.
  • 9KING JR TE, BROWN KK, RAGHU G, et al. BUILD-3: a ran- domized, controlled trial of bosentan in idiopathic pulmonary fi- brosis[J]. American Journal of Respiratory and Critical Care Medi- cine, 2011, 184(1): 92-99.
  • 10LEY B, COLLARD HR, KING JR TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis[J]. Ameri- can Journal of Respiratory and Critical Care Medicine, 2011, 183(4): 431-440.

同被引文献48

  • 1高海锋.肿瘤标记物CA125检测在诊断肺癌中的价值[J].实用医技杂志,2008,15(9):1217-1218. 被引量:5
  • 2崔瑷,代华平.特发性肺纤维化诊治进展:从“专家共识”到以循证医学证据为基础的“诊治指南”[J].中国医学前沿杂志(电子版),2012,4(1):51-54. 被引量:13
  • 3Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fi- brosis: a disease with similarities and finks to cancer biolog)']J]. Eur Respir J, 2010, 35(3): 496-504.
  • 4Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011, 183(6): 788-824.
  • 5Goto T, Maeshima A, Oyamada Y, ct al. Idiopathic pulmonary fibrosis as a prognostic factor in non-small cell lung cancer[J]. Int J Clin Oncol, 2014, 19(2): 266-273.
  • 6Pedroza M, Le T'F, Lewis K, et al. STAT-3 contributes to pul- monary fibrosis through epithelial injury and fibroblast-myofi- broblast differentiation[J]. Faseb Journal, 2016, 30(1): 129-140.
  • 7Du Bois RM. Strategies for treating idiopathic pulmonary fibrosis[J]. Nat Rev Drug Discov, 2010, 9(2): 129-140.
  • 8Liu M, Ren D, Wu D, et al. Stem cell and idiopathic pulmonary fibrosis: mechanisms and treatment[J]. Curr Stem Cell Res Ther, 2015, 10(2): 466-476.
  • 9Calabrese F, Lunardi F, Giacometti C, et al. Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibro- sis: clinicopathological corrlationa[J]. Thorax, 2008, 63(9): 795- 802.
  • 10魏善和,朱召明,闫丽妲,邓芳,吴丽.肺癌患者SCC、CYFRA211、NSE和CEA检测的临床意义[J].牡丹江医学院学报,2010,31(1):18-21. 被引量:12

引证文献5

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部